A phase II randomized double-blind placebo-controlled multi-center study to assess the safety tolerability and preliminary efficacy of empagliflozin among patients with residual kidney function receiving hemodialysis for the treatment of end-stage kidney disease

Go Back to All Clinical Trials

A phase II randomized double-blind placebo-controlled multi-center study to assess the safety tolerability and preliminary efficacy of empagliflozin among patients with residual kidney function receiving hemodialysis for the treatment of end-stage kidney disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
End Stage Renal Disease (esrd)
Age: Between 18 Year(s) - 90 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Undergoing in-center, three-times weekly hemodialysis for treatment of end-stage renal disease (ESRD);
2. Less than 1 year since dialysis initiation.

You may not be eligible for this study if the following are true:

1. Currently incarcerated;
2. Life expectancy, kidney transplant, change in dialysis modality, or change to non-participating HD unit anticipated within 6 months;
3. Allergy to study medication;
4. Type 1 Diabetes.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies